Background: Gastric cancer (GC) is the fifth most common malignancy worldwide. Early detection of precancerous conditions—atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia—is vital for surveillance. Objectives: To assess the accuracy of single high-quality endoscopy (HQE) in detecting advanced GPCs and to identify risk factors for AG, IM, and dysplasia. Methods: A retrospective review of 442 gastroscopies (2017–2022) at a single center. Endoscopic findings were compared with histology, including OLGA/OLGIM staging, dysplasia, and Helicobacter pylori (H. pylori) status. Results: The study population comprised 319 women (72.17%) and 123 men (27.83%), with a mean age of 59 years (SD: 12.53). AG, as defined by OLGA and OLGIM staging, was identified in 90 patients (20.36%) and 50 patients (11.31%), respectively. A total of 44 cases of de novo gastric dysplasia were observed, while HP infection was confirmed in 37 individuals (8.37%). We observed similar low sensitivity for detection of advanced OLGA (32.5%), OLGIM (40%), and dysplasia (19.7%) with relatively high specificity (~89%). Advanced AG and IM peaked at ages 51–53. Risk factors for advanced OLGIM included male sex (OR 2.26; p < 0.001) and presence of dysplasia (OR 2.09; p = 0.02). Dysplasia was positively associated with AG (OR 2.03; p < 0.001) and IM (OR 2.21; p < 0.001) but inversely associated with a family history of GC (OR 0.44; p < 0.001). Conclusions: A single HQE can help exclude advanced GPCs, but due to low sensitivity, gastric mapping biopsies remain crucial. Males are at increased risk of extensive IM. Family history of GC was linked to lower OLGA/OLGIM stages.
29 January 2022 in Journal of Education, Health and Sport
A 69-year-old patient was admitted to the Department of Cardiology due to an accidental finding on a chest X-ray, enlarged heart outline, accompanied by worsening of heart failure to NYHA II with LVEF, about 30%. In the X-ray description, an enlargement of the left atrium silhouette with local calcifications. The patient underwent TTE, confirming the presence of a pedunculated tumor of the left atrium attached to the ceiling measuring 3.5x3.5x2.2 cm. Due to the ischemic heart disease manifestation patient uderwent coronarography confirming the presence of single-vessel coronary artery disease with changes in the middle segment of the LAD. Patient was treated with CABG LIMA-LAD surgery and removeal the left atrial tumor. Post operation tissue material prooved the preseance of left atrium myxoma. The postoperative course was uneventful, the patient was discharged home.
Background: Gastric cancer (GC) is the fifth most common malignancy worldwide. Early detection of precancerous conditions - atrophic gastritis (AG), intestinal metaplasia (IM), and dysplasia - is vital for surveillance. Objectives: To assess the accuracy of single high-quality endoscopy (HQE) in detecting advanced GPCs and to identify risk factors for AG, IM, and dysplasia. Methods: A retrospective review of 442 gastroscopies (2017–2022) at a single center. Endoscopic findings were compared with histology, including OLGA/OLGIM staging, dysplasia, and Helicobacter pylori (HP) status. Results: The study population comprised 319 women (72.17%) and 123 men (27.83%), with a mean age of 59 years (SD: 12.53). AG, as defined by OLGA and OLGIM staging, was identified in 90 patients (20.36%) and 50 patients (11.31%), respectively. A total of 44 cases of de novo gastric dysplasia were observed, while HP infection was confirmed in 37 individuals (8.37%). We proved similar low sensitivity for detection of advanced OLGA (32,5%), OLGIM (40%) and dysplasia (19.7%) with relatively high specificity (~89%). Advanced AG and IM peaked at ages 51–53. Risk factors for advanced OLGIM included male sex (OR 2.26; P < 0.001) and presence of dysplasia (OR 2.09; P = 0.02). Dysplasia was positively associated with AG (OR 2.03; P < 0.001) and IM (OR 2.21; P < 0.001), but inversely associated with a family history of GC (OR 0.44; P < 0.001). Conclusions: A single HQE can help exclude advanced GPCs, but due to low sensitivity, gastric mapping biopsies remain crucial. Males are at increased risk of extensive IM. Family history of GC was linked to lower OLGA/OLGIM stages.
18 August 2023 in Pacing and Clinical Electrophysiology
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is one of the fastest-growing liver disorders worldwide. It is driven by obesity and type 2 diabetes. Taste perception plays a key role in appetite regulation and nutrition, also influencing other liver diseases progression. This review summarizes past and current evidence on taste disorders in liver diseases and their clinical implications. A narrative review of PubMed, Web of Science, Google Scholar, and Research Gate databases was conducted using selected MeSH terms. Taste disturbances have been reported in viral hepatitis, cirrhosis, Wilson’s disease, amebic liver abscesses, and NAFLD/MASLD, as well as in nutritional deficiencies (zinc, magnesium, vitamin A, branched-chain amino acids). Dysgeusia was linked to reduced appetite, sarcopenia, malnutrition, altered food preferences, and obesity risk in MASLD. Taste impairments worsen with liver dysfunction progression. Several drugs (e.g., interferon, metronidazole) contribute to dysgeusia. Zinc deficiency was the most consistent factor. Glucagon-like peptide-1 (GLP-1) receptor modulators, affecting appetite and sweet/umami perception, appear promising in MASLD therapy. Taste disorders are prevalent and still under-recognized in populations with liver diseases. The cause of these disorders remains unclear. Most of available studies affecting nutrients deficiencies are outdated. More research targeting molecular pathways of taste modulation (e.g., GLP-1 receptors), as well as determining the prevalence and clinical consequences of dysgeusia in specific liver disease stages is needed to better understand how micronutrient deficiencies and medications affect taste disorders.